Proximity of TPR and NTRK1 rearranging loci in human thyrocytes.

Cancer Res

Department of Experimental Oncology Operative Unit Molecular Mechanisms of Cancer Growth and Progression, Istituto Nazionale Tumori, Milan, Italy.

Published: April 2005

Chromosomal rearrangements are frequently associated with cancer; the mechanisms underlying their cell-type specificity are poorly understood. Papillary thyroid carcinomas are marked by a high frequency of chromosome rearrangements involving the RET and NTRK1 tyrosine kinase receptor genes and producing RET and TRK oncogenes. An explanation for the propensity of thyrocytes to undergo gene rearrangements has been recently proposed by Nikiforova and colleagues, who showed that the recombination between RET and H4 is favored by the loci proximity in interphase nuclei. We investigated whether the spatial proximity is a contributing factor also in the generation of the thyroid-specific TRK oncogenes. The distance between NTRK1 and its oncogenic partner TPR was determined by two-color fluorescence in situ hybridization and two-dimensional microscopy. A three-dimensional reconstruction of the data was also done. We show that the two loci in thyrocytes nuclei display a distance reduced with respect to peripheral blood lymphocytes, thus supporting the notion that spatial proximity of translocation-prone gene loci may favor gene rearrangements.

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-4294DOI Listing

Publication Analysis

Top Keywords

trk oncogenes
8
gene rearrangements
8
spatial proximity
8
proximity
4
proximity tpr
4
tpr ntrk1
4
ntrk1 rearranging
4
loci
4
rearranging loci
4
loci human
4

Similar Publications

NTRK (neurotropic tropomyosin receptor kinase)-rearranged spindle cell tumours represent a rare group of molecularly defined soft tissue neoplasms. These tumours, excluding infantile fibrosarcomas, are characterised by NTRK gene rearrangements and exhibit a range of histomorphologies, including spindle, epithelioid or rhabdoid cells with invasive growth. Their prognosis correlates with histological grade, and surgical resection is the primary treatment.

View Article and Find Full Text PDF

NTRK fusion promotes tumor migration and invasion through epithelial-mesenchymal transition and closely interacts with ECM1 and NOVA1.

BMC Cancer

December 2024

Institute of Integrative Medicine, Department of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.

Background: The NTRK fusion gene is a rare cancer driver and a typical representative "diamond mutation". Its unique role in tumor progression is highly important for the clinical diagnosis and treatment of patients with tumors. We searched for NTRK fusion-positive patients in our hospital.

View Article and Find Full Text PDF

fusions are oncogenic drivers for multiple tumor types. Therefore, the development of selective tropomyosin receptor kinase (TRK) inhibitors, including larotrectinib and entrectinib, has been transformative in the context of clinical management, given the high rates of responses to these drugs, including intracranial responses in patients with brain metastases. Given their promising activity in pan-cancer cohorts, larotrectinib and entrectinib received U.

View Article and Find Full Text PDF
Article Synopsis
  • The ROS1 proto-oncogene is linked with receptor tyrosine kinases and plays a significant role in treating ROS1 fusion-positive non-small cell lung cancer (NSCLC) using FDA-approved TKIs like crizotinib and entrectinib, though these medications face challenges such as resistance and limited brain penetration.
  • Repotrectinib, a new macrocyclic TKI, was created to tackle resistance mutations and enhance brain distribution, showing strong effectiveness in the TRIDENT-1 trial with high response rates in both TKI-naïve and TKI-pretreated patients.
  • The trial showed that 79% of TKI-naïve patients achieved an objective response and had longer progression
View Article and Find Full Text PDF
Article Synopsis
  • Neurotrophic receptor tyrosine kinases TrkA, TrkB, and TrkC play different roles in neuroblastoma, a childhood cancer, with TrkA linked to better outcomes and lower disease stages, while TrkB is often found in more aggressive forms associated with MYCN amplification.
  • This study used advanced mass spectrometry to analyze proteins and phosphoproteins in neuroblastoma cells, revealing substantial data (4,907 proteins, 16,744 phosphosites) that highlights the distinct signaling of these Trk receptors and their interaction with MYCN status.
  • The findings could lead to better understanding and treatment strategies for neuroblastoma by clarifying how different Trk receptors influence the
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!